It appears that unnecessary and avoidable serial routine laboratory tests are ordered for about 11% of patients with systemic lupus erythematosus (SLE) at each office visit, according to a recent survey of medical practices that treat these patients.
Despite the high direct medical costs of treating systemic lupus erythematosus (SLE), opportunities exist for improving SLE treatment rates, treatment appropriateness, and referral to specialists, according to research presented at the Academy of Managed Care Pharmacy annual meeting.
Belimumab is the first new drug for systemic lupus erythematosus (SLE) in more than 50 years and the first in its class to be approved by the US Food and Drug Administration (FDA).
Paris, France—A study presented at the 2014 European League Against Rheumatism (EULAR) Congress reports that a sizable proportion of selected patients with lupus can stop therapy without triggering new disease flares for up to 5 years.
Adults with childhood systemic lupus erythematosus (cSLE) are significantly less likely to be employed than adults with adult-onset SLE (aSLE), according to a large, prospective, longitudinal study by Erica F. Lawson, MD, Department of Pediatrics, Division of Rheumatology, University of California, San Francisco, and colleagues.
A limited number of studies have evaluated associations between peripheral neuropathies with autoantibody patterns and aspects of systemic lupus erythematosus (SLE) activity.
Whistler, BC—A Toronto team has succeeded in completely tapering three-quarters of the patients with whom they attempted this discontinuation of immunosuppressants. Their analysis suggests immunosuppressant tapering is most likely to succeed in patients who are in clinical remission, who are on a low dose of corticosteroids, and who are tapered slowly.
By Wayne Kuznar San Diego, CA—High doses patients with of glucocorticoids in the treatment of patients with systemic lupus erythematosus (SLE) are associated with a greater incidence of adverse events (AEs) and greater healthcare resource utilization compared with low doses or no use of glucocorticoids, found Wei-Shi Yeh, PhD, Associate Director, Global Market Access, Biogen Idec, Weston, MA, and colleagues.
By Wayne Kuznar San Diego, CA—The selection of treatment for patients with systemic lupus erythematosus and thrombocytopenia should hinge on the differential diagnosis and the pathogenic mechanisms involved. Three possible options include splenectomy, B-cell depletion, and platelet augmentation, said Brady L. Stein, MD, MHS, Assistant Professor of Medicine, Northwestern University, Chicago, IL, at the 2013 American College of Rheumatology meeting.
Easy on the prednisone, maximize immunomodulators, look for noncalcified plaque By Wayne Kuznar San Diego, CA—Expanded use of hydroxychloroquine and limited use of prednisone are 2 strategies in the management of patients with systemic lupus erythematosus (SLE), said Michelle A. Petri, MD, MPH, Professor of Medicine, Johns Hopkins University, Baltimore, MD, at the 2013 American College of Rheumatology meeting.
Page 2 of 5
Results 11 - 20 of 45
  • Rheumatology Practice Management
  • Lynx CME
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology